Arbor's hospital portfolio grows as Eisai sheds US rights to Gliadel
This article was originally published in Scrip
Executive Summary
Eisai is continuing to rationalize operations and hone its focus on major products against a background of revenue pressures, this time through an agreement to divest to Arbor Pharmaceuticals the US rights to Gliadel Wafer (polifeprosan 20 with carmustine implant).